Grundläggande statistik
| CIK | 1725160 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zentalis Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2026 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| May 21, 2026 |
Exhibit 99.1 Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 •In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events •Activi |
|
| May 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2026 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| May 12, 2026 |
zntlq12026corporatedeck Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care Corporate Presentation | May 2026 Nasdaq: ZNTL Zentalis Pharmaceuticals, Inc. |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2026 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| May 12, 2026 |
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress Exhibit 99.1 Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress •400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting advancement in registration-intended trials •DENALI Phase 2 trial topline readout expected by year-end 2026, with potential to support accelerated approval |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2026 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-360 |
|
| May 5, 2026 |
Exhibit 99.1 Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer •Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrolling •ASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval pathway, pending F |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39263 Zentalis Pharm |
|
| April 17, 2026 |
Exhibit 99.1 Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 •Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer •Real-world data demonstrate Cyclin |
|
| April 17, 2026 |
ex992-leeetalazenointnbc METHODS Analysis of pharmacogenomic and proteomic datasets • Comparison of Cyclin E1 protein levels in serous ovarian cancer (SOC) and basal‑like breast cancer was determined from TCGA pan‑cancer analysis. |
|
| April 17, 2026 |
ex993-jeongetalrealworl METHODS (cont'd) BOX1: Cyclin E1 status determination The definition of Cyclin E1 positivity depends on purpose (predictive, prognostic), available measurement (RNA, proteomics, IHC) and study design (observation, investigation, retrospective, etc). |
|
| April 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2026 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| April 9, 2026 |
ex991-zntlcorporateprese Corporate Presentation April 2026 Nasdaq: ZNTL 2 Zentalis Pharmaceuticals, Inc. |
|
| April 9, 2026 |
Exhibit 99.2 Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer •Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups •Azenosertib therapeutic profile supports Phase |
|
| April 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 9, 2026 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-3 |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39263 Zentalis Pharm |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2026 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| March 26, 2026 |
Exhibit 10.14 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv). Such excluded information is information the registrant customarily and actually treats as private or confidential and is not material. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporati |
|
| March 26, 2026 |
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates Exhibit 99.1 Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates •On track for DENALI Part 2a dose confirmation in 1H 2026 •DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval •On track to initiate the ASPENOVA Phase 3, randomized, confirmatory trial in 1H 2026 •Expanding azenosertib potential in ovarian can |
|
| January 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2026 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82 |
|
| January 9, 2026 |
zntlcorporatepresentatio Corporate Presentation January 2026 Nasdaq: ZNTL 2 Zentalis Pharmaceuticals, Inc. |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
|
| November 10, 2025 |
zntlcorporatepresentatio Corporate Presentation November 2025 Nasdaq: ZNTL 2 Zentalis Pharmaceuticals, Inc. |
|
| November 10, 2025 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $280.7 million cash, cash equivalents and marketable securities |
|
| November 10, 2025 |
Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv). Such excluded information is information the registrant customarily and actually treats as private or confidential and is not material. RELEASE AGREEMENT This Release Agreement (the “Agreement”) is entered into by and among Andrea Paul (“Executive”), Zentalis Pharmaceuticals, |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82 |
|
| August 26, 2025 |
Exhibit 99.1 Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise SAN DIEGO — August 26, 2025 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potent |
|
| August 6, 2025 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $303.4 million cash, cash equivalents and marketable securitie |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
|
| August 6, 2025 |
zntlpresentationq22025 Corporate Presentation August 2025 Nasdaq: ZNTL 2 Zentalis Pharmaceuticals, Inc. |
|
| August 6, 2025 |
Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. RELEASE AGREEMENT This Release Agreement (the “Agreement”) is entered into by and among Mark Lackner, Ph.D. (“Executive”), Zentalis Pharmaceuticals, Inc. (“Pa |
|
| August 6, 2025 |
Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Consulting Agreement This Consulting Agreement (the “Agreement”) is dated as of April 25, 2025, between Zentalis Pharmaceuticals, Inc., a Delaware corporation |
|
| June 18, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-3 |
|
| June 2, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| June 2, 2025 |
METHODS Figure 3. Phase 1, Single‑Arm, Open‑Label, Multicenter, Dose‑Escalation Study Design and Patient Flow Key Eligibility Criteria • Age ≥18 years • Metastatic/Stage IV CRC • BRAFV600E mutation • Measurable disease per RECIST v1.1 • Adequate hematological and organ function • ECOG PS 0 or 1 • PD after 1-3 previous systemic regimens for metastatic disease • No prior treatment with a WEE1 inhibi |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 20, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| May 14, 2025 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketabl |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
|
| May 14, 2025 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Zentalis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2022 Employment Induc |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| May 14, 2025 |
As filed with the Securities and Exchange Commission on May 14, 2025 As filed with the Securities and Exchange Commission on May 14, 2025 Registration No. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39263 Zentalis Pharm |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2025 |
Figure 3. RECIST Responders Showed a Higher Molecular Response Rate P = 0.012 Odds ratio (95% CI) = 0.26 (0.090-0.75) MR+ (N) MR- (N) RECIST Responder 20 5 RECIST Non-responder 50 48 PPV (95% CI) 28% (19-40%) NPV (95% CI) 91% (80-96%) 20/25 (80% MRR) cOR 40/71 (56% MRR) SD 9/26 (35% MRR) 80% of responders per RECIST had a molecular response 91% of patients without molecular response were non-respo |
|
| April 28, 2025 |
Figure 2. Combination of Azenosertib with Encorafenib + Cetuximab (E+C) Demonstrates Synergy in BRAFV600E-Driven CRC Models In Vitro 0 20 40 60 80 100 % In hi bi ti on 0 20 40 60 80 100 0 20 40 60 80 100 0 20 40 60 80 100 0 0.031 0.063 0.125 0.25 0.5 0 0.063 0.125 0.25 0.5 1 0 0.031 0.063 0.125 0.25 0.5 0 0.031 0.063 0.125 0.25 0.5 0.05 0.025 0.013 0.006 0.003 0.001 8e-4 4e-4 2e-4 0 0.1 0.05 0.025 |
|
| April 28, 2025 |
Figure 2. RB1 Loss Is Associated With Azenosertib Sensitivity in TP53‑Mutant Cancer Cell Lines 0.001 0.01 0.1 1 10 100 -1.0 -0.5 0.0 0.5 1.0 1.5 Concentration (µM) G R V al ue 0.001 0.01 0.1 1 10 100 -1.0 -0.5 0.0 0.5 1.0 1.5 Concentration (µM) G R V al ue DMS53 TP53 mut/ RB1 wt TP53 mut/ RB1 mut SW1271 NCI-H1048 NCI-H1963 NCI-H446 NCI-H510 NCI-H524 NCI-H209 NCI-H526 MDA-MB-231 MDA-MB-468 BT549 TP |
|
| April 28, 2025 |
a993liuetalazenomodelsi Figure 2. Azenosertib Is a Selective WEE1 Inhibitor and Modulates WEE1‑Dependent Pathways in Cancer Cell Lines -10 -8 -6 0 0 0 0.1 0.3 1 0 0. 2 0. 5 1 2 0 0. 01 0. 02 5 0. 05 0. 1 1 2 3 4 5 6 7 8 9 10 11 Dose (µM) Dose (µM) p-CDK1 (Y15)Target engagement CDK1 Cyclin E1 Cyclin B1 pS10-HH3 pS345-CHK1 γH2AX (S139) Cleaved Caspase-3 (D175) Vinculin Lane p-TCTP (S64) TCTP WEE1 p- |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| April 2, 2025 |
Zentalis Pharmaceuticals, Inc. 10275 Science Center Dr., Suite 200 San Diego, California 92121 Zentalis Pharmaceuticals, Inc. 10275 Science Center Dr., Suite 200 San Diego, California 92121 April 2, 2025 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Zentalis Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 26, 2025 File No. 333-286122 To whom it may concern: Pursuant to R |
|
| April 1, 2025 |
April 1, 2025 Julie Eastland Chief Executive Officer Zentalis Pharmaceuticals, Inc. |
|
| March 26, 2025 |
, effective November 13, 2024, between Zentalis Pharmaceuticals, Inc., Zeno Management, Inc. and Exhibit 10.16 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. RELEASE AGREEMENT This Release Agreement (the “Agreement”) is entered into by and among Cam Gallagher (“Executive”), Zentalis Pharmaceuticals, Inc. (“Parent” |
|
| March 26, 2025 |
November 13, 2024, between Zentalis Pharmaceuticals, Inc. and Kimberly Blackwell, M.D. Exhibit 10.14 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Consulting Agreement This Consulting Agreement (the “Agreement”) is dated as of November 13, 2024, between Zentalis Pharmaceuticals, Inc., a Delaware corpora |
|
| March 26, 2025 |
Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan, as Exhibit 10.5.1 ZENTALIS PHARMACEUTICALS, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in |
|
| March 26, 2025 |
Exhibit 4.3 ZENTALIS PHARMACEUTICALS, INC. INDENTURE Dated as of, 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 2 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series. 6 Section 2.2 |
|
| March 26, 2025 |
Sales Agreement, dated May 3, 2021, by and between the registrant and Leerink Partners LLC. Exhibit 1.2 Zentalis Pharmaceuticals, Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT May 3, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Zentalis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows: 1. Issuance |
|
| March 26, 2025 |
Zeno Management, Inc. and Kimberly Blackwell, M.D. Exhibit 10.13 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. RELEASE AGREEMENT This Release Agreement (the “Agreement”) is entered into by and among Kimberly Blackwell, M.D. (“Executive”), Zentalis Pharmaceuticals, Inc |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39263 Zentalis Pharm |
|
| March 26, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Zentalis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registr |
|
| March 26, 2025 |
As filed with the Securities and Exchange Commission on March 26, 2025 As filed with the Securities and Exchange Commission on March 26, 2025 Registration No. |
|
| March 26, 2025 |
Non-Employee Director Compensation Program Exhibit 10.3 ZENTALIS PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Effective January 1, 2025 Non-employee members of the board of directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the Company’s 2 |
|
| March 26, 2025 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused s |
|
| March 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| March 26, 2025 |
Consulting Agreement, dated November 13, 2024, between Zentalis Pharmaceuticals, Inc. and Exhibit 10.17 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Consulting Agreement This Consulting Agreement (the “Agreement”) is dated as of November 13, 2024, between Zentalis Pharmaceuticals, Inc., a Delaware corpora |
|
| March 26, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 Zentalis Pharmaceuticals, Inc. Insider Trading Compliance Policy Introduction This Insider Trading Compliance Policy (this “Policy”) sets forth procedures designed to help persons covered by this Policy comply with U.S. federal and state insider trading laws. U.S. federal and state laws prohibit trading in the Securities (defined below) of a company while in possession of material non |
|
| March 26, 2025 |
Employment Agreement, dated November 13, 2024, between Zeno Management, Inc. and Exhibit 10.11 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company” |
|
| March 26, 2025 |
, between Zeno Management, Inc. and Exhibit 10.10 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company” |
|
| March 17, 2025 |
simpkinssgoxdenalixpart Exhibit 99.2 Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes From Part 1b of the DENALI Study (GOG-3066) Fiona Simpkins1,Alexandra Leary2, Lyndsay Willmott3, Bradley J. Monk4, Jean-Sébastien Frenel5, David C. Starks6, Meena Okera7, Angeles Alvarez Secord8, David M. O’Malley9, Lainie Martin1, Kaissa Ouali2, Mar |
|
| March 17, 2025 |
Exhibit 99.1 Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response- |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| February 14, 2025 |
EX-1 2 ex1.htm EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in |
|
| February 4, 2025 |
EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0. |
|
| January 29, 2025 |
Exhibit 99.1 Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy cohorts in key clinical studies, well |
|
| January 29, 2025 |
Corporate Event January 29, 2025 Nasdaq: ZNTL Exhibit 99.2 2 Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this presentation t |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 29, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 8 |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2025 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 8 |
|
| January 28, 2025 |
Exhibit 99.1 Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate event to be held on January 29, 2025 at 8:00am ET to provide key updates on azenoserti |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K/A —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-3926 |
|
| December 6, 2024 |
Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. |
|
| November 14, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427061d18sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (the “S |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 |
|
| November 13, 2024 |
Exhibit 99.1 Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib Julie Eastland appointed Chief Executive Officer, President and Director Ingmar Bruns, M.D., appointed Chief Medical Officer Scott Myers appointed to the Board of Directors as Chairperson SAN DIEGO — November 13, 2024 — Zentalis® Pharmaceuticals, Inc. (Nasd |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
|
| November 12, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GZentalisPh.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* (Name of Issuer) Zentalis Pharmaceuticals Inc (Title of Class |
|
| November 12, 2024 |
, 2024, among Zentalis Pharmaceuticals, Inc., Zeno Management, Inc., and Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. 1 RELEASE AGREEMENT This Release Agreement (the “Agreement”) is entered into by and among Diana Hausman, M.D. (“Executive”), Zentalis Pharmaceuticals, Inc. ( |
|
| November 6, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 sc13gazentalis.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Zentalis Pharmaceuticals, Inc. (Name of Issuer – as specified in its charter) Common Stock, $0.001 par value per share (Title of Class of Securities) 98943L107 (CUSIP Number) October 31, 2024 (Date of Event which Requires Filing |
|
| November 4, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GZentalisPh.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* (Name of Issuer) Zentalis Pharmaceuticals Inc (Title of Class |
|
| October 18, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 ZentalisPharmaInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ZENTALIS PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 98943L107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul |
|
| October 17, 2024 |
October 17, 2024 Cam Gallagher Interim Chief Financial Officer Zentalis Pharmaceuticals, Inc. |
|
| October 10, 2024 |
October 10, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| October 7, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 ZENTALIS PHARMACEUTICALS INC COMMON STOCK Cusip #98943L107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #98943L107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,071,674 Item 6: 0 Item 7: 5,075,837 Item 8: |
|
| September 16, 2024 |
Exhibit 99.1 Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024 SAN DIEGO — September 16, 2024 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molec |
|
| September 16, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 |
|
| September 12, 2024 |
September 12, 2024 Cam Gallagher Interim Chief Financial Officer Zentalis Pharmaceuticals, Inc. |
|
| August 9, 2024 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress $426.4M cash, cash equivalents and marketable securities as of June 30, 2024; Projected cash runway into mid-2026 SAN DIEGO — August 9, 2024 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated smal |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
|
| August 9, 2024 |
, 2024, among Zentalis Pharmaceuticals, Inc., Zeno Management, Inc., and Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. 1 RELEASE AGREEMENT This Release Agreement (the “Agreement”) is entered into by and among Melissa Epperly (“Executive”), Zentalis Pharmaceuticals, Inc. (“Par |
|
| June 21, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-3 |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| June 3, 2024 |
zentaliscorporatepresent Corporate Presentation Nasdaq: ZNTL June 2024 Exhibit 99. |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 7, 2024 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024 and into 2025 Final results from Phase 1 study of azenosertib in combination with gemcitabine in adult and pediatric patients with relapse |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-360 |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39263 Zentalis Pharm |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 5, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-3 |
|
| April 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 9, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-3 |
|
| April 9, 2024 |
Corporate Presentation Nasdaq: ZNTL April 2024 Exhibit 99.1 2 Forward Looking Statements and Disclaimer Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All |
|
| February 29, 2024 |
Exhibit 4.3 ZENTALIS PHARMACEUTICALS, INC. INDENTURE Dated as of, 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series. 6 Section 2.2 |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Zentalis Pharmaceuticals, Inc. |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 29, 2024 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Zentalis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2022 Employment Induc |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 29, 2024 |
Sales Agreement, dated May 3, 2021, by and between the registrant and Leerink Partners LLC. Exhibit 1.2 Zentalis Pharmaceuticals, Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT May 3, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Zentalis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows: 1. Issuance |
|
| February 27, 2024 |
9, 2024, between Zentalis Pharmaceuticals, Inc. and Carrie Brown Exhibit 10.16 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. CONSULTING AGREEMENT This CONSULTING AGREEMENT (the “Agreement”) is dated as of January 19, 2024, between ZENTALIS PHARMACEUTICALS, INC., a Delaware corporat |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 |
|
| February 27, 2024 |
Exhibit 10.9.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDMENT OF LEASE THIS AMENDMENT OF LEASE, made as of the 11th day of December, 2023 (this "Amendment"), by and between ESRT 1359 BROADWAY, L.L.C., a Delaw |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39263 Zentalis Pharm |
|
| February 27, 2024 |
Exhibit 10.23 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company”) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the “Parent”), and Mark Lackner (“Executive”), and shall be effective as of Executive’s commencement of service as the C |
|
| February 27, 2024 |
entalis Pharmaceuticals, Inc. Policy for Erroneously Exhibit 97 ZENTALIS PHARMACEUTICALS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION The Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein |
|
| February 27, 2024 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates Robust azenosertib clinical development plan ongoing and on track with multiple clinical catalysts anticipated, including monotherapy and combination data readouts in gynecological and other cancer types during 2024 Strengthened management team with appointments of Diana Hausman, M.D., as Chief M |
|
| February 27, 2024 |
1 General Release of All Claims This General Release of All Claims (“Release”) is entered into as of this 2nd day of January, 2024, among Kevin Bunker, Ph. |
|
| February 27, 2024 |
List of Subsidiaries of Zentalis Pharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of Zentalis Pharmaceuticals, Inc. Legal Name of Subsidiary Jurisdiction of Organization Zeno Management, Inc. Delaware Zeno Pharmaceuticals, Inc. Delaware Zeno Alpha, Inc. Delaware K-Group Alpha, Inc. Delaware K-Group Beta, Inc. Delaware Zentalis Pharmaceuticals Australia Pty Ltd. Australia |
|
| February 27, 2024 |
Exhibit 10.15 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 1 RELEASE AGREEMENT This Release Agreement (the “Agreement”) is entered into by and among Carrie Brownstein, M.D. (“Executive”), Zentalis Pharmaceuticals, In |
|
| February 27, 2024 |
9, 2024, between Zeno Management, Inc., and Diana Hausman, M.D. Exhibit 10.24 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of January 19, 2024, by and between Zeno Management, Inc., a Delaware corporation (the “Company”) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the “Parent”), and Diana Hausman, M.D. (“Executive”), and shall be effective as of the date of Executive’s commencement of employment with |
|
| February 27, 2024 |
ransition and Release Agreement, dated November 1, 2023, 1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). |
|
| February 27, 2024 |
onsulting Agreement, dated November 1, 2023, between Zentalis Pharmaceutic Exhibit 10.20 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. CONSULTING AGREEMENT This CONSULTING AGREEMENT (the “Agreement”) is dated as of November 1, 2023, between ZENTALIS PHARMACEUTICALS, INC., a Delaware corporat |
|
| February 27, 2024 |
Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan, as amended Exhibit 10.6.1 1 ZENTALIS PHARMACEUTICALS, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined i |
|
| February 27, 2024 |
Non-Employee Director Compensation Program Exhibit 10.3 ZENTALIS PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Effective January 1, 2024 Non-employee members of the board of directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the Company’s 2 |
|
| February 15, 2024 |
Amended and Restated Bylaws of Zentalis Pharmaceuticals, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ZENTALIS PHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 NOTICE OF BUSINESS TO BE BROUGHT BEFORE A MEETING 2 2.5 NOTICE OF NOMINATIONS FOR ELECTION |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 |
|
| February 14, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243573d20sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (the “Sh |
|
| February 13, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02328-zentalispharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Zentalis Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 98943L107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate b |
|
| February 13, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1097782213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 98943L107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98943L107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 9, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98943L107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 9, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No.4 ZENTALIS PHARMACEUTICALS INC COMMON STOCK Cusip #98943L107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #98943L107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 10,336,125 Item 6: 0 Item 7: 10,336,971 Item 8: 0 Item 9: 10,336,971 |
|
| January 29, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us98943l1070012924.txt us98943l1070012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) ZENTALIS PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 98943L107 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| January 25, 2024 |
Exhibit 99.1 Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio Manager, Appointed Chief Business Officer NEW YORK & SAN DIEGO, January 25, 2024 - Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage |
|
| January 25, 2024 |
ZNTL / Zentalis Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING ZENTALIS PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 98943L107 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHED |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 19, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 8 |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2024 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82 |
|
| January 8, 2024 |
Exhibit 99.1 Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform - Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 - - Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs - - Zentalis to receive up-front payment of $35 million in cash and Immunome common stock |
|
| December 11, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 sc13g-zentalis.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zentalis Pharmaceuticals, Inc. (Name of Issuer – as specified in its charter) Common Stock, $0.001 par value per share (Title of Class of Securities) 98943L107 (CUSIP Number) November 30, 2023 (Date of Event which Requires Filing |
|
| November 17, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment SC 13G 1 tm2331049d3sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) |
|
| November 6, 2023 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on track for first NDA submission in a gynecologic malignancy in 2026 Sharing key clinical milest |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 8 |
|
| November 6, 2023 |
Corporate Presentation Nasdaq: ZNTL November 2023 Exhibit 99.2 2 Forward Looking Statements and Disclaimer Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. A |
|
| October 10, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SC 13G 1 sc13geventide.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Zentalis Pharmaceuticals, Inc. (Name of Issuer – as specified in its charter) Common Stock, $0.001 par value per share (Title of Class of Securities) 98943L107 (CUSIP Number) September 30, 2023 (Date of Event which Requires Filing of |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82 |
|
| September 13, 2023 |
Corporate Presentation September 2023 Nasdaq: ZNTL 2 Forward Looking Statements and Disclaimer Zentalis Pharmaceuticals, Inc. |
|
| September 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| August 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| August 9, 2023 |
zentaliscorporatedeckaug Corporate Presentation August 2023 Nasdaq: ZNTL Exhibit 99. |
|
| August 9, 2023 |
Exhibit 10.1 Execution Version [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. THIRD AMENDED AND RESTATED LICENSE AGREEMENT between Recurium IP Holdings, LLC, and Zeno Management, Inc. Dated: June 5, 2023 TABLE OF CONTE |
|
| August 9, 2023 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients who received intermittent dosing Identified azenosertib monotherapy RP2D, which more than doubles exposure levels, maintains safety and improves tolerability with no trea |
|
| June 20, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98943L107 (CUSIP Number) Gregory A. Brown Matrix Capital Management Company LP Bay Colony Corporate Center 1000 Winter Street, Suite 4500 Waltham, |
|
| June 16, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF ZENTALIS PHARMACEUTICALS, INC. ZENTALIS PHARMACEUTICALS, INC. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware, does hereby certify as follows: 1.That, at a meeting of the Board of Directors of the Corporation, resolutions were duly adopted recommending a |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-3 |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-3 |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-3 |
|
| June 15, 2023 |
Exhibit 1.1 11,032,656 Shares ZENTALIS PHARMACEUTICALS, INC. COMMON STOCK (PAR VALUE $0.001 PER SHARE) UNDERWRITING AGREEMENT June 15, 2023 1 June 15, 2023 Morgan Stanley & Co. LLC Jefferies LLC SVB Securities LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New Yor |
|
| June 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Zentalis Pharmaceuticals, Inc. |
|
| June 15, 2023 |
11,032,656 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-255769 PROSPECTUS SUPPLEMENT (to Prospectus dated May 4, 2021) 11,032,656 Shares Common Stock We are offering 11,032,656 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “ZNTL.” On June 14, 2023, the last reported sale price of our common stock on The Nasdaq Global Market was $24.63 p |
|
| June 15, 2023 |
ZENTALIS PHARMACEUTICALS, INC. Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated June 15, 2023 Relating to Prospectus Dated May 4, 2021 Registration Statement No. |
|
| June 6, 2023 |
ex993-zentalisinvestorwe Azenosertib Clinical Update Dose Selection, Monotherapy and Chemotherapy Combinations Efficacy and Safety and Ongoing Development June 2023 Nasdaq: ZNTL 2 Forward Looking Statement and Disclaimer Zentalis Pharmaceuticals, Inc. |
|
| June 6, 2023 |
Exhibit 99.1 Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability wit |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| June 6, 2023 |
ex992-zentaliscorporated Corporate Presentation June 2023 Nasdaq: ZNTL 2 Forward Looking Statement and Disclaimer Zentalis Pharmaceuticals, Inc. |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 5, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| June 5, 2023 |
ex991-smithasco2023xznx A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor Azenosertib (ZN-c3) in Patients (Pts) With Acute Myeloid Leukemia (AML) Catherine Smith1, Pankit Vachhani2, Guillermo Garcia Manero3, Nicole Grieselhuber4, Guru Subramanian Guru Murthy5, Astha Bhatia6, Jatinder Arora6, Hooman Izadi7, Anthony Fiorino7, Raajit Rampal8 1Division of Hematology |
|
| June 5, 2023 |
ex992-liuetalasco2023 Correlation of Cyclin E1 Expression and Clinical Outcomes in a Phase 1b Dose-Escalation Study of Azenosertib (ZN-c3), a WEE1 inhibitor, in Combination with Chemotherapy (CT) in Patients (pts) with Platinum-Resistant or Refractory (R/R) Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer (EOC) Joyce Liu1, Siqing Fu2, Gary Richardson3, Zivko Vranjes4, Tarek Meniawy5, Catherine Shannon6, Erika P. |
|
| May 26, 2023 |
Exhibit 99.1 Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR |
|
| May 26, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| May 10, 2023 |
Form of Indemnification Agreement for Directors and Officers Exhibit 10.1 Zentalis Pharmaceuticals, Inc. Indemnification Agreement THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , between Zentalis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering indemnification and advanc |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-36 |
|
| May 10, 2023 |
Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AGREEMENT OF SUBLEASE AGREEMENT OF SUBLEASE (the “Sublease Agreement” or “Sublease”), dated as of the 6th day of March, 2023, by and between ZENTALIS PHARMACE |
|
| May 10, 2023 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor, in 1H 2023 Positive Phase 1b azenosertib + chemotherapy clinical data in ovarian cancer to be presented ahead of original guidance at |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39263 Zentalis Pharm |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| April 26, 2023 |
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib Company also announces collaborations with Foundation Medicine and Roche Diagnostics to advance the development of azenosertib NEW YORK & SAN DIEGO, April 26, 2023 - Zentalis® Pharmaceuticals, Inc. |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 17, 2023 |
zentaliscorporatedeck-ap 1 CORPORATE PRESENTATION April 2023 Exhibit 99.2 2 Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this |
|
| April 17, 2023 |
Exhibit 99.1 Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023 Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy combination study, including data on CCNE1 amplificat |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| March 10, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / SUN ANTHONY Y - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of S |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82- |
|
| March 9, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-3 |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39263 Zentalis Pharm |
|
| March 1, 2023 |
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates On track to declare monotherapy RP2D for potentially first-in-class/best-in-class Wee1 inhibitor, azenosertib (ZN-c3), and provide program updates and potential paths to registration in 1H 2023 Pursuing Cyclin E1 as a patient enrichment strategy for azenosertib monotherapy in ovarian cancer; Cyclin E1 preclin |
|
| March 1, 2023 |
Exhibit 10.16 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company”) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the “Parent”), and Andrea Paul (“Executive”), and shall be effective as of February 28, 2023 (the “Effective Date”). WHE |
|
| March 1, 2023 |
Exhibit 10.12 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company”) and a wholly-owned subsidiary of Zentalis Pharmaceuticals, Inc. (the “Parent”), and Kimberly Blackwell, M.D. (“Executive”), and shall be effective as of February 28, 2023 (the “Effectiv |
|
| March 1, 2023 |
Exhibit 10.18.3 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. COMPOUND SPECIFIC PATENT RIGHTS AMENDMENT TO THE SECOND AMENDED AND RESTATED LICENSE AGREEMENT between Recurium IP Holdings, LLC, and Zeno Management, Inc. |
|
| March 1, 2023 |
, 2023, between Zeno Management, Inc. and Kevin Bunker, Ph.D. Exhibit 10.15 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company”) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the “Parent”), and Kevin Bunker, Ph.D. (“Executive”), and shall be effective as of February 28, 2023 (the “Effective Dat |
|
| March 1, 2023 |
Exhibit 10.13 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company”) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the “Parent”), and Cam Gallagher (“Executive”), and shall be effective as of February 28, 2023 (the “Effective Date”). W |
|
| March 1, 2023 |
zentaliscorporatedeck-ma 1 CORPORATE PRESENTATION March 2023 2 Zentalis Pharmaceuticals, Inc. |
|
| March 1, 2023 |
Exhibit 10.14 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company”) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the “Parent”), and Carrie Brownstein (“Executive”), and shall be effective as of February 28, 2023 (the “Effective Date” |
|
| March 1, 2023 |
Amended and Restated Employment Agreement, effective as of Exhibit 10.11 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company”) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the “Parent”), and Melissa Epperly (“Executive”), and shall be effective as of February 28, 2023 (the “Effective Date”). |
|
| March 1, 2023 |
Non-Employee Director Compensation Program Exhibit 10.3 ZENTALIS PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Effective January 5, 2023 Non-employee members of the board of directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the Company’s 2 |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82-3 |
|
| March 1, 2023 |
List of Subsidiaries of Zentalis Pharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of Zentalis Pharmaceuticals, Inc. Legal Name of Subsidiary Jurisdiction of Organization Zeno Management, Inc. Delaware Zeno Pharmaceuticals, Inc. Delaware Zeno Alpha, Inc. Delaware Zeno Beta, Inc. Delaware Zeno Gamma, Inc. Delaware K-Group Alpha, Inc. Delaware K-Group Beta, Inc. Delaware Zentalis Pharmaceuticals Australia Pty Ltd. Australia Zentalis Eta, Inc. Delaware |
|
| February 14, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / TYBOURNE CAPITAL MANAGEMENT (HK) LTD Passive Investment SC 13G 1 sch13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Zentalis Pharmaceuticals, LLC (Name of Issuer) Common Stock (Title of Class of Securities) 98943L107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d994238313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 98943L107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 14, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G/A 1 zntl13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ZENTALIS PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 98943L107 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 |
|
| February 13, 2023 |
Employment Agreement, dated February 8, 2023, between Zeno Management, Inc. and Iris Roth. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of February 8, 2023, by and between Zeno Management, Inc. |
|
| February 13, 2023 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98943L107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 9, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 ZENTALIS PHARMACEUTICALS INC COMMON STOCK Cusip #98943L107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #98943L107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,908,512 Item 6: 0 Item 7: 7,909,176 Item 8: |
|
| February 9, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Zentalis Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 98943L107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 7, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING ZENTALIS PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 98943L107 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHED |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98943L107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 1, 2023 |
ZNTL / Zentalis Pharmaceuticals Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us98943l1070020123.txt us98943l1070020123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) ZENTALIS PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 98943L107 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| January 9, 2023 |
EX-99.1 2 zentaliscorporatedeck-ja.htm EX-99.1 1 CORPORATE PRESENTATION January 2023 Exhibit 99.1 2 Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All stat |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 —————————————— ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) —————————————— Delaware 001-39263 82 |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ?????????????? FORM 8-K ?????????????? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2022 ?????????????? ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ?????????????? Delaware 001-39263 8 |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
|
| November 9, 2022 |
Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into by and between Zeno Management, Inc., a Delaware corporation (the ?Company?) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the ?Parent?), and Kevin Bunker, Ph.D. (?Executive?), and shall be effective as of September 26, 2022 (the ?Effective Dat |
|
| November 9, 2022 |
Exhibit 10.2 RELEASE AGREEMENT This Release Agreement (the ?Agreement?) is entered into by and among Dimitris Voliotis, M.D. (?Employee?), Zentalis Pharmaceuticals, Inc. (?Parent?) and Zeno Management, Inc. (the ?Zeno Management,? and together with Parent, the ?Company?), effective as of the Effective Date (as defined below). Recitals WHEREAS, Employee is a party to that certain Employment Agreeme |
|
| November 9, 2022 |
Employment Agreement, dated September 15, 2022, between Zeno Management, Inc. and Carrie Brownstein Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of September 15, 2022, by and between Zeno Management, Inc., a Delaware corporation (the ?Company?) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the ?Parent?), and Carrie Brownstein (?Executive?), and shall be effective as of the date of Executive?s commencement of employment with |
|
| November 9, 2022 |
1 CORPORATE PRESENTATION November 2022 2 Zentalis Pharmaceuticals, Inc. (?we,? ?us,? ?our,? ?Zentalis? or the ?Company?) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to |
|
| November 9, 2022 |
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates Six sponsored studies with potentially first-in-class Wee1 inhibitor, ZN-c3, ongoing and continuing dose optimization work, as drug continues to show improved tolerability in initial safety data from monotherapy Phase 2 USC trial announced today Identified Cyclin E driven high-grade serous ovarian cancer |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001- |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ?????????????? FORM 8-K ?????????????? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2022 ?????????????? ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ?????????????? Delaware 001-39263 |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ?????????????? FORM 8-K ?????????????? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2022 ?????????????? ZENTALIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ?????????????? Delaware 001-39263 |
|
| August 9, 2022 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Zentalis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2022 Employment Induc |
|
| August 9, 2022 |
Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update Strengthened leadership team with the appointment of additional industry veterans, including CEO Dr. Kimberly Blackwell and Chairman Dave Johnson Received a $25 million equity investment from Pfizer, with plans to jointly advance and expand clinical development of ZN-c3; added Pfizer?s Dr. Ad |
|
| August 9, 2022 |
Employment Agreement, dated June 23, 2022, between Zeno Management, Inc. and Andrea Paul EXHIBIT 10.8# EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this "Agreement') is entered into as of June 23, 2022, by and between Zeno Management, Inc., a Delaware corporation (the "Company") and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the "Parent"), and Andrea Paul ("Executive"), and shall be effective as of the date of Executive's commencement of employment with the Compan |
|
| August 9, 2022 |
C O R P O R AT E P R E S E N TAT I O N A u g u s t 2 0 2 2 Forward-Looking Statements and Disclaimer Zentalis Pharmaceuticals, Inc. |
|
| August 9, 2022 |
As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39263 Zentalis Pharmaceuticals, Inc. |
